<p>Leerink Partners 分析师 Faisal Khurshid 今天维持了对 Rhythm Pharmaceuticals 的买入评级，并设定了目标价为 142.00 美元。</p>
<h3>在 TipRanks Premium 上享受 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Khurshid 关注医疗保健行业，重点关注 aTyr Pharma、Rhythm Pharmaceuticals 和 Nurix Therapeutics 等股票。根据 TipRanks 的数据，Khurshid 推荐股票的平均回报率为 55.8%，成功率为 59.02%。</p>
<p>除了 Leerink Partners，Rhythm Pharmaceuticals 还在 12 月 12 日的报告中获得了摩根士丹利的 Michael Ulz 的买入评级。然而，在同一天，TR | OpenAI – 4o 对 Rhythm Pharmaceuticals (NASDAQ: RYTM) 重申了持有评级。</p>

RYTM

<p>Leerink Partners 的分析师 Faisal Khurshid 对 Rhythm Pharmaceuticals 维持了买入评级，目标价为 142.00 美元。Khurshid 覆盖医疗保健行业，推荐股票的平均回报率为 55.8%，成功率为 59.02%。Rhythm Pharmaceuticals 还获得了摩根士丹利的买入评级，而 TR 则重申了持有评级</p>

<p>Leerink Partners analyst Faisal Khurshid maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $142.00.</p>
<div class="lb-trans"><p>Leerink Partners 分析师 Faisal Khurshid 今天维持了对 Rhythm Pharmaceuticals 的买入评级，并设定了目标价为 142.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Rhythm Pharmaceuticals, and Nurix Therapeutics. According to TipRanks, Khurshid has an average return of 55.8% and a 59.02% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Khurshid 关注医疗保健行业，重点关注 aTyr Pharma、Rhythm Pharmaceuticals 和 Nurix Therapeutics 等股票。根据 TipRanks 的数据，Khurshid 推荐股票的平均回报率为 55.8%，成功率为 59.02%。</p>
</div><p>In addition to Leerink Partners, Rhythm Pharmaceuticals also received a Buy from Morgan Stanley’s Michael Ulz in a report issued on December 12. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).</p>
<div class="lb-trans"><p>除了 Leerink Partners，Rhythm Pharmaceuticals 还在 12 月 12 日的报告中获得了摩根士丹利的 Michael Ulz 的买入评级。然而，在同一天，TR | OpenAI – 4o 对 Rhythm Pharmaceuticals (NASDAQ: RYTM) 重申了持有评级。</p>
</div>

Leerink Partners 坚持对 Rhythm Pharmaceuticals (RYTM) 的买入评级